Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentre, Non-interventional, Observational, Cohort Study to Evaluate the Long Term Clinical, Patient Reported and Health Care Resource Utilization Effects of an Early Response to Certolizumab Pegol (Cimzia®) in Rheumatoid Arthritis Patients in Daily Clinical Practice in the United Kingdom and Eire.

NCT01288287 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01288287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01288287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentre, Non-interventional, Observational, Cohort Study to Evaluate the Long Term Clinical, Patient Reported and Health Care Resource Utilization Effects of an Early Response to Certolizumab Pegol (Cimzia®) in Rheumatoid Arthritis Patients in Daily Clinical Practice in the United Kingdom and Eire.
Lead sponsor
UCB Pharma
Phase
Observational
Overall status
Completed
Start date
July 31, 2011
Completion date
December 31, 2014
Enrollment
149 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis,rheumatoid